Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination: A single-arm open-label interventional study – final study results-Reference-Cited by-同舟云学术

Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination: A single-arm open-label interventional study – final study results

Published:2024-03 Issue: Volume:10 Page:35-43
ISSN:2772-7076
Container-title:IJID Regions
language:en
Short-container-title:IJID Regions

Author:

Makhema Joseph^ORCID,Shava Emily^ORCID,Izu Alane^ORCID,Gaolathe Tendani,Kuate Lesego,Walker Adam,Carty Lucy,Georgiou Panayiotis,Kgathi Coulson,Choga Wonderful T.^ORCID,Sekoto Tumalano,Seonyatseng Ngozana,Mogashoa Tuelo^ORCID,Maphorisa Comfort N.^ORCID,Mohammed Terence,Ntalabgwe Tshenolo,Frank Tshepho T.,Matlhaku Boitumelo,Diphoko Ame,Phindela Thandie,Kaunda Agripa,Kgari Poloko,Kanyakula Thomas^ORCID,Palalani Gape,Phakedi Isabella,Mmalane Mompati,Taylor Sylvia,Moyo Sikhulile

Funder

AstraZeneca

AstraZeneca UK Limited

Fogarty International Center

Bill and Melinda Gates Foundation

Publisher

Elsevier BV

Reference22 articles.

1. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK;Voysey;Lancet,2021

2. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial;Ramasamy;Lancet,2021

3. Country progress report-Botswana,2020

4. Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey;Gaolathe;Lancet HIV,2016

5. COVID-19 vaccine hesitancy in Africa: a scoping review;Ackah;Glob Health Res Policy,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2 Antibody Level after Homologous and Heterologous Booster Vaccines: an 18-month Longitudinal Observational Cohort Study in Indonesia;The Open Public Health Journal;2024-07-31